EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer

Catharina J P Op 't Hoog iD, Niven Mehra, Benthe van der Weij, Erik Olofsen, Diederik M Somford, Inge M van Oort, Paul Hamberg, Nielka P van Erp iD, Emmy Boerrigter

Clinical Pharmacokinetics · 2026-05 · 65 (5) · 763-772

DOI: 10.1007/s40262-026-01640-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 04.05.2026. Verfasst von Catharina J P Op 't Hoog und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Morphine, Prostatic Neoplasms, Analgesics, Opioid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas Pharma, Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Pain management in patients with prostate cancer receiving enzalutamide is challenging owing to its high potential for drug-drug interactions. Morphine is generally preferred because of its favorable metabolic profile, but the effect of enzalutamide on the pharmacokinetics of morphine is unclear. The objective of this study was to assess whether a drug-drug interaction exists between enzalutamide and morphine in patients with prostate cancer. METHODS: In a multicenter two-arm parallel study, 24 men with prostate cancer received morphine with enzalutamide (n = 12) and without enzalutamide (n = 12). Plasma concentrations of morphine and its active metabolite morphine-6-glucuronide were measured. Pharmacokinetic parameters were calculated using a non-compartmental analysis. Geometric mean ratios (GMR) of the area under the plasma concentration-time curves were calculated. No clinically relevant interaction was defined if 90% of the confidence interval (CI) of the GMR of morphine was within the range of 0.5-2.0. RESULTS: Morphine exposure was similar between both groups, with the 90% CI falling within the range of 0.5-2.0 (GMR 1.01; 90% CI 0.77-1.31). The exposure of morphine-6-glucuronide was increased with enzalutamide (GMR 1.77; 90% CI 1.43-2.17). CONCLUSIONS: The exposure of morphine was unaffected by enzalutamide, while morphine-6-glucuronide exposure was increased. Because of the inconclusive potency of morphine-6-glucuronide and its uncertain ability to cross the blood-brain barrier, the increase is likely of modest clinical significance. Therefore, morphine and enzalutamide can be safely combined when starting at a low dose and titrated based on efficacy and tolerability. CLINICAL TRIAL REGISTRATION: NCT05339672.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinMorphineProstatic NeoplasmsAnalgesics, OpioidHumansMaleNitrilesBenzamidesDrug InteractionsAgedMorphine DerivativesMiddle Aged

Substanzen

enzalutamideNitrilesBenzamidesPhenylthiohydantoinMorphineAnalgesics, OpioidMorphine Derivativesmorphine-6-glucuronide

Autor:innen und Institutionen

  • Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Anaesthesiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Department of Urology, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.

ORCID-Profile: Catharina J P Op 't Hoog, Nielka P van Erp

Förderung

  • Astellas Pharma, Netherlands

Zitieren

APA

Op 't Hoog, C. J. P., Mehra, N., van der Weij, B., Olofsen, E., Somford, D. M., van Oort, I. M., Hamberg, P., van Erp, N. P., & Boerrigter, E. (2026). Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer. Clinical Pharmacokinetics, 65(5), 763-772. https://doi.org/10.1007/s40262-026-01640-6

Vancouver

Op 't Hoog CJP, Mehra N, van der Weij B, Olofsen E, Somford DM, van Oort IM, et al. Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer. Clinical Pharmacokinetics. 2026;65(5):763-772. doi:10.1007/s40262-026-01640-6

BibTeX
@article{OptHoog2026,
  author = {Op 't Hoog, Catharina J P and Mehra, Niven and van der Weij, Benthe and Olofsen, Erik and Somford, Diederik M and van Oort, Inge M and Hamberg, Paul and van Erp, Nielka P and Boerrigter, Emmy},
  title = {Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {5},
  pages = {763--772},
  doi = {10.1007/s40262-026-01640-6}
}
Kostenlos starten →